Perspectives of Postmenopausal Breast Cancer

T he majority (about 65%) of nonmetastatic breast cancer survivors are prescribed adjuvant endocrine therapy (AET) with agents such as estrogen receptor agonists/antagonists and/or aromatase inhibitors (Burstein et al., 2010). AET is a long-term therapy currently administered for five years, although an up-dated American Society of Clinical Oncology guideline, reflecting emerging data, recommended that women completing five years of adjuvant tamoxifen should be offered continuation of AET for a total of 10 years to further improve morbidity and mortality outcomes (Burstein et al., 2014; Davies et al., 2012). Patients with breast cancer receiving any kind of AET may experience multiple, persistent symptoms, including vasomotor symptoms, sexual dysfunction, insomnia, fatigue, anxiety, depression, and arthralgia